PPAR马受体:一种新的目标,可以改善早产婴儿的发病率
Suresh Victor1, Ben Forbes2, Anne Greenough3
1Centre for the Developing Brain, Department of Perinatal Imaging and Health, School of Biomedical Engineering and Imaging Sciences, King's College London, St. Thomas' Hospital, London SE1 7EH, UK.
Pharmaceuticals (Basel, Switzerland)
|November 25, 2023
概括
皮奥格利塔是一种PPARγ激动剂,在减少BPD和改善极度早产婴儿的神经发育方面表现有前途. 在临床试验开始之前,需要进一步研究合适的液体配方.
科学领域:
- 新生儿医学 新生儿医学
- 药理学 药理学是指药理学的学科.
- 发展生物学 发展生物学
背景情况:
- 极度早产 (妊娠28周以下) 会导致高死亡率和发病率,包括支气管肺功能失调 (BPD) 和脑.
- 过氧体增殖器激活受体马 (PPARγ) 信号传递对发育至关重要,并且在早产新生儿中不太活跃.
- 目前对极度早产婴儿的治疗选择在预防长期并发症方面有效性有限.
研究的目的:
- 评估PPARγ激动剂pioglitazone在极度早产婴儿中降低BPD发生率和改善神经发育结果方面的潜力.
- 探索皮奥格利塔与新生儿疾病相关的抗炎机制.
- 在临床前模型中评估pioglitazone的安全性和耐受性.
主要方法:
- 关于皮奥格利塔在新生儿动物模型中对早产并发症相关的影响的临床前数据的审查.
- 分析PPARγ信号传递及其由皮奥格利塔调节在新生儿发育中的作用.
- 检查生殖毒理学研究,以评估胎儿安全.
主要成果:
- 皮奥格利塔在动物模型中表现出对BPD,死性肠球炎和脑损伤的保护作用.
- PPARγ信号与早产期大脑发育有关,多形态与神经发育障碍相关.
- 皮奥格利塔在胎儿毒理学研究中耐受性良好,具有改善血糖控制等潜在益处.
结论:
- 皮奥格利塔对极度早产婴儿具有显著的治疗潜力,可能减轻BPD并增强神经发育.
- 开发一种合适的pioglitazone液体配方是启动临床试验的先决条件.
- 皮奥格利塔治疗的预期好处似乎超过了潜在的安全问题,需要进一步调查.
相关概念视频
01:15G Protein-coupled Receptors
12.1K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.1K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
188
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
188
01:24Glucagon-like Receptor Agonists
329
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
329